0001209191-18-033173.txt : 20180524 0001209191-18-033173.hdr.sgml : 20180524 20180524185339 ACCESSION NUMBER: 0001209191-18-033173 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180524 FILED AS OF DATE: 20180524 DATE AS OF CHANGE: 20180524 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kelly David George CENTRAL INDEX KEY: 0001624670 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38503 FILM NUMBER: 18859237 MAIL ADDRESS: STREET 1: C/O HORIZON PHARMA PLC STREET 2: ADELAIDE CHAMBERS, PETER STREET CITY: DUBLIN 8 STATE: L2 ZIP: NONE ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Iterum Therapeutics plc CENTRAL INDEX KEY: 0001659323 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BLOCK 2 FLOOR 3, HARCOURT CENTRE STREET 2: HARCOURT STREET CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: (872) 225-6077 MAIL ADDRESS: STREET 1: BLOCK 2 FLOOR 3, HARCOURT CENTRE STREET 2: HARCOURT STREET CITY: DUBLIN STATE: L2 ZIP: 2 FORMER COMPANY: FORMER CONFORMED NAME: Iterum Therapeutics Ltd DATE OF NAME CHANGE: 20151124 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2018-05-24 0 0001659323 Iterum Therapeutics plc ITRM 0001624670 Kelly David George C/O ITERUM THERAPEUTICS PLC, BLK 2 FL. 3, HARCOURT CENTRE, HARCOURT ST. DUBLIN L2 2 IRELAND 1 0 0 0 Series A Preferred Shares Ordinary Shares 9548 D Stock Option (Right to Buy) 3.14 2025-08-14 Ordinary Shares 2546 D Stock Option (Right to Buy) 3.30 2027-09-11 Ordinary Shares 636 D The Series A Preferred Shares are convertible into Ordinary Shares of the Issuer at the option of the holder. The Series A Preferred Shares will automatically convert into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. Not applicable. The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of August 15, 2016 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of September 12, 2017 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. /s/ David G. Kelly 2018-05-24 EX-24 2 attachment1.htm EX-24 DOCUMENT
POWER OF ATTORNEY

	Know all by these presents that the undersigned hereby constitutes and appoints
each Corey N. Fishman and Judith M. Matthews of Iterum Therapeutics plc (the
"Company") and Alan Hambelton, Colleen Burns and Brian Woodard of Cooley LLP,
signing individually, the undersigned's true and lawful attorneys-in fact and
agents to:

	(1)	prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the Securities and Exchange Commission (the "SEC") a Form ID,
including amendments thereto, and any other documents necessary or appropriate
to obtain codes and passwords enabling the undersigned to make electronic
filings with the SEC of reports required by Section 16(a) of the Securities
Exchange Act of 1934, as amended (the "Exchange Act") or any rule or regulation
thereunder;

	(2)	prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the SEC Forms 3, 4 and 5 (including amendments thereto and joint
filing agreements in connection therewith) with respect to the securities of the
Company in accordance with Section 16(a) of Exchange Act and the rules
thereunder;

	(3)	do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to prepare and execute any such Form 3, 4 or 5
(including amendments thereto and joint filing agreements in connection
therewith) and file such Forms with the SEC and any stock exchange,
self-regulatory association or any other authority; and

	(4)	take any other action of any type whatsoever in connection with the
foregoing that, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required of the undersigned, it being
understood that the documents executed by the attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as the attorney-in-fact may approve in the
attorney-in-fact's discretion.

	The undersigned hereby grants to each such attorney in fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney in fact, or such attorney
in fact's substitute or substitutes, shall lawfully do or cause to be done by
virtue of this power of attorney and the rights and powers herein granted.  The
undersigned acknowledges that the foregoing attorneys-in-fact, and their
substitutes, in serving in such capacity at the request of the undersigned, are
not assuming (nor is the Company assuming) any of the undersigned's
responsibilities to comply with Section 16 of the Exchange Act.

	This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
Company and the attorneys-in-fact.  This Power of Attorney revokes any other
power of attorney that the undersigned has previously granted to representatives
of the Company and Cooley LLP.

	IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of the date written below.

Dated:  March 8, 2018


By: 	/s/ David G. Kelly				David G. Kelly
	Signature					Printed Name